This systematic review included three randomized, placebo-controlled studies, in a total of 76 patients with obesity and metabolic syndrome, and found no differences in fasting plasma glucose, hepatic insulin sensitivity, BMI, lipid markers, and fecal SCFA levels after FMT across all studies. This evidence concerns the gene INS and Obesity.